CCA
IMMU

Column Capital Advisors’s Immunomedics Inc IMMU Stock Holding History

Column Capital Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-235
Closed -$4K – 825
2019
Q4 		$4K Buy
+235
New +$4.15K ﹤0.01% 562

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Capital Advisors's IMMU Position: Q1 2020 in Review

Column Capital Advisors sold out of Immunomedics Inc (IMMU) in Q1 2020, closing a stake of 235 shares — an estimated $4K sold.

Column Capital Advisors first reported a position in IMMU in Q4 2019 and held it in 1 quarter. The position peaked at $4K in Q4 2019. 220 funds tracked by Wall St. Rank hold IMMU as of Q1 2020.

  • Column Capital Advisors reported no remaining Immunomedics Inc position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 235 Immunomedics Inc shares in Q1 2020, an estimated $4K.
  • Column Capital Advisors first reported a position in Immunomedics Inc in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's Immunomedics Inc position peaked at $4K in Q4 2019.
  • 220 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.